Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy relationship (1: 1: 1)Planning ...

Poor saliva control (sialorrhoea) represents a considerable burden to paediatric patients with neurodevelopmental ...

Arrowhead Pharmaceuticals, Inc. ( NASDAQ: ARWR) H.C. Wainwright 27th Annual Global Investment Conference September 9, 2025 10:30 AM EDT ...

UCB Canada Inc. is proud to announce that the pan-Canadian Pharmaceutical Alliance (pCPA) has successfully concluded negotiations for PrZILBRYSQ® ...

HBC has today released a whitepaper demonstrating how its bioactive peptide ingredient ProGo® uniquely provides complete GLP-1 support. To maximize the effect of GLP-1 therapy, lean muscle mass needs ...

A dangerous new drug adulterant is spreading through America’s illicit opioid supply, and it’s making overdoses significantly harder to reverse. Medetomidine, a veterinary sedative normally used to ...

The legal claims against Novo Nordisk are not about banning the drug. They are about accountability and informed consent. The core ...

Interim results from the CAReS trial highlight ART27.13's potential to combat cancer-related weight loss, offering hope for ...

Scientists have created a pre-clinical weight loss drug combining GLP-1, GIP, glucagon and peptide YY hormones to match ...

This extreme potency means that even tiny amounts can have devastating effects. Users experiencing medetomidine-laced drug ...

Scientists have developed a new 4-in-1 weight loss drug combining GLP-1, GIP, glucagon, and PYY hormones, aiming to match bariatric surgery-level results while reducing obesity-related risks like ...